ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation

Transfusion

Volumn 43, Issue 8, 2003, Pages 1153-1161

  Worel, Nina ^a   Kalhs, Peter ^b   Keil, Felix ^b   Prinz, Erika ^b   Moser, Karin ^b   Schulenburg, Axel ^b   Mitterbauer, Margit ^b   Mannhalter, Christine ^b   Mayr, Wolfgang R ^b   Schwarzinger, Ilse ^b   Höcker, Paul ^b   Lechner, Klaus ^b   Greinix, Hildegard T ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; COTRIMOXAZOLE; CYCLOSPORIN; FLUDARABINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ADULT; AGED; ARTICLE; BLOOD GROUP ABO SYSTEM; BLOOD GROUP INCOMPATIBILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; ERYTHROCYTE APLASIA; FEMALE; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOLYSIS; HOSPITALIZATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; MALE; MORBIDITY; MORTALITY; SURVIVAL RATE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT OUTCOME; VIRUS INFECTION; WHOLE BODY RADIATION;

ABO BLOOD-GROUP SYSTEM; ADULT; AGED; BLOOD GROUP INCOMPATIBILITY; CENTRAL NERVOUS SYSTEM DISEASES; DISEASE PROGRESSION; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOSPITALIZATION; HUMANS; IMMUNE SYSTEM DISEASES; INFECTION; MALE; MIDDLE AGED; RECURRENCE; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0042931282     PISSN: 00411132     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1537-2995.2003.00465.x     Document Type: Article

References (41)

1. Petz LD. Hemolysis associated with transplantation (editorial). Transfusion 1998;38:224-8.
2. Sniecinski IJ, Oien L, Petz LD, Blume KG. Immunohematologic consequences of major ABO-mismatched bone marrow transplantation. Transplantation 1988;45:530-4.
3. Mielcarek M, Leisenring W, Torok-Storb B, Storb R. Graft-versus-host disease and donor-directed hemagglutinin titers after ABO-mismatched related and unrelated marrow allografts: evidence for a graft-versus-plasma cell effect. Blood 2000;96:1150-6.
4. Bensinger WI, Buckner CD, Thomas ED, Clift RA. ABO-incompatible marrow transplants. Transplantation 1982;33:427-9.
5. Klumpp TR. Immunohematologic complications of bone marrow transplantation. Bone Marrow Transplant 1991;8:159-70.
6. Worel N, Greinix HT, Schneider B, et al. Regeneration of erythropoiesis after related- and unrelated-donor BMT or peripheral blood HPC transplantation: major ABO mismatch means problems. Transfusion 2000;40:543-50.
7. Oziel-Taieb S, Faucher-Barbey C, Chabannon C, et al. Early and fatal immune haemolysis after so-called "minor" ABO-incompatible peripheral blood stem cell allotransplantation. Bone Marrow Transplant 1997;19:1155-6.
8. Bolan CD, Childs RW, Procter JL, Barrett AJ, Leitman SF. Massive immune haemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility. Br J Haematol 2001;112:787-95.
9. Worel N, Greinix HT, Keil F, et al. Severe immune hemolysis after minor ABO-mismatched allogeneic peripheral blood progenitor cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning. Transfusion 2002;42:1293-301.
10. Benjamin RJ, McGurk S, Ralston MS, et al. ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation. Transfusion 1999;39:179-87.
11. Bar BM, Van Dijk BA, Schattenberg A, et al. Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow. Bone Marrow Transplant 1995;16:793-9.
12. Lee JH, Lee KH, Kim S, et al. Anti-A isoagglutinin as a risk factor for the development of pure red cell aplasia after major ABO-incompatible allogeneic bone marrow transplantation. Bone Marrow Transplant 2000;25:179-84.
13. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet 1999;353:1755-9.
14. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-4000.
15. Giralt S, Estey E, Albitar M, et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997;89:4531-6.
16. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998;91:756-63.
17. Childs RW, Clave E, Tisdale J, et al. Successful treatment of metastatic renal cell carcinoma with nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J Clin Oncol 1999;17:2044-9.
18. Bolan CD, Leitman SF, Griffith LM, et al. Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation. Blood 2001;98:1687-94.
19. Hansen JA, Mickelson EM, et al. Clinical bone marrow transplantation: donor selection and recipient monitoring. In: Rose NR, De Macario EC, Fahey JL, et al., eds. Manual of clinical laboratory immunology. 4th ed. Washington (DC): American Society for Microbiology; 1992:850.
20. Dupont B, Yang SY. Histocompatibility. In: Forman SJ, Blume KJ, Thomas ED, eds. Bone marrow transplantation. Boston: Blackwell, 1994:26.
21. Fischer GF, Faé I, Petrasek M, et al. A combination of two distinct in vitro amplification procedures for DNA typing of HLA-DRB and -DQB1 alleles. Vox Sang 1995;69:328-35.
22. Rowlings PA, Przepiorka D, Klein JP, et al. IBMTR severity index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997;97:855-64.
23. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression. Blood 1981;57:267-76.
24. Schulenburg A, Watkins-Riedel T, Greinix HT, et al. CMV monitoring after peripheral blood stem cell and bone marrow transplantation by pp65 antigen and quantitative PCR. Bone Marrow Transplant 2001;28:765-8.
25. Peake IR, Bowen D, Bignell P, et al. Family studies and prenatal diagnosis in severe von Willebrand's disease by polymerase chain reaction amplification of variable number of tandem repeat region of the von Willebrand factor gene. Blood 1990;76:555-61.
26. Nishimura DY, Murray JC. A tetranucleotide repeat for the F13B locus. Nucleic Acids Res 1992;20:1167.
27. Weber JL, May PE. Abundant class of human DNA polymorphisms which can be typed using the polymerase chain reaction. Am J Hum Genet 1989;44:388-96.
28. Widman FK, ed. Technical manual. 9th ed. Bethesda: American Association of Blood Banks; 1985.
29. Lapierre Y, Rigal D, Adam J, et al. The gel test: a new way to detect red cell antigen-antibody reactions. Transfusion 1990;30:109-13.
30. Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002;34:1094-7.
31. Ljungman P. Herpes virus infections in immunocompromised patients: problems and therapeutic interventions. Ann Med 1993;25:329-33.
32. Martino R, Subira M. Invasive fungal infections in hematology: new trends. Ann Hematol 2002;81:233-43.
33. Bornhauser M, Ordemann R, Paaz U, et al. Rapid engraftment after allogeneic ABO-incompatible peripheral blood progenitor cell transplantation complicated by severe hemolysis. Bone Marrow Transplant 1997;19:295-7.
34. Kalhs P, Brugger S, Schwarzinger I, et al. Microangiopathy following allogeneic marrow transplantation: association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis. Transplantation 1995;60:949-57.
35. Zeigler ZR, Shadduck RK, Nemunaitis J, et al. Bone marrow transplant-associated thrombotic microangiopathy: a case series. Bone Marrow Transplant 1995;15:247-53.
36. Fuge R, Bird JM, Fraser A, et al. The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation. Br J Haematol 2001;113:58-64.
37. Van der Plas RM, Schiphorst ME, Huizinga EG, et al. Von Willebrand factor proteolysis is deficient in classic, but not in bone marrow transplantation-associated, thrombotic thrombocytopenic purpura. Blood 1999;93:3798-802.
38. Mohty M, Faucher C, Vey N, et al. High rate of secondary viral and bacterial infections in patients undergoing allogeneic bone marrow mini-transplantation. Bone Marrow Transplant 2000;26:251-5.
39. Chakrabarti S, Kottaridis P, Ogormon P, et al. High incidence of early and late CMV infection and delayed immune reconstitution after allogeneic transplants with nonmyeloablative conditioning using CAMPATH (anti-CD52 antibody). Blood 2000;96(Suppl 1):586a.
40. Junghanss C, Boeckh M, Carter R, et al. Incidence of herpes virus infections following nonmyeloablative allogeneic stem cell transplantation. Blood 2000;96(Suppl 1):188a.
41. Mehta J, Powles R, Sirohi B, et al. Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia? Bone Marrow Transplant 2002;29:853-9.